Partition coefficients for gadolinium chelates in the normal myocardium: Comparison of gadopentetate dimeglumine and gadobenate dimeglumine

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 3, 2012, Pages 733-737

  Kawel, Nadine ^a   Nacif, Marcelo ^a   Santini, Francesco ^b,c   Liu, Songtao ^a   Bremerich, Jens ^b   Arai, Andrew E ^d   Bluemke, David A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

gadobenate dimeglumine; gadopentetate dimeglumine; modified Look Locker inversion recovery, partition coefficient; T1 mapping

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; FEMALE; HEART MUSCLE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL;

ADULT; CHELATING AGENTS; COMPUTER SIMULATION; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MEGLUMINE; METABOLIC CLEARANCE RATE; MODELS, CARDIOVASCULAR; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84865311488     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23651     Document Type: Article

References (18)

1. Jellis C, Martin J, Narula J, Marwick TH,. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010; 56: 89-97.
2. Wei JY,. Age and the cardiovascular system. N Engl J Med 1992; 327: 1735-1739.
3. Kumar A, Meyerrose G, Sood V, Roongsritong C,. Diastolic heart failure in the elderly and the potential role of aldosterone antagonists. Drugs Aging 2006; 23: 299-308. (Pubitemid 43830661)
4. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010; 122: 900-909.
5. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109: 1250-1258. (Pubitemid 38379570)
6. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52: 1574-1580.
7. Messroghli DR, Plein S, Higgins DM, et al. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Radiology 2006; 238: 1004-1012. (Pubitemid 43289933)
8. Arheden H, Saeed M, Higgins CB, et al. Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging. Radiology 2000; 215: 520-528. (Pubitemid 30237855)
9. Sharma P, Socolow J, Patel S, Pettigrew RI, Oshinski JN,. Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans. J Magn Reson Imaging 2006; 23: 323-330. (Pubitemid 43364058)
10. Wendland MF, Saeed M, Lauerma K, et al. Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI. Magn Reson Med 1997; 37: 448-456. (Pubitemid 27107971)
11. Messroghli DR, Rudolph A, Abdel-Aty H, et al. An open-source software tool for the generation of relaxation time maps in magnetic resonance imaging. BMC Med Imaging 2010; 10: 16.
12. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-542. (Pubitemid 34262671)
13. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-221. (Pubitemid 44406181)
14. Schlosser T, Hunold P, Herborn CU, et al. Myocardial infarct: depiction with contrast-enhanced MR imaging-comparison of gadopentetate and gadobenate. Radiology 2005; 236: 1041-1046. (Pubitemid 41170871)
15. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M,. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging 2010; 3: 727-734.
16. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson 2011; 13: 16.
17. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010; 122: 138-144.
18. Thornhill RE, Prato FS, Wisenberg G, White JA, Nowell J, Sauer A,. Feasibility of the single-bolus strategy for measuring the partition coefficient of Gd-DTPA in patients with myocardial infarction: independence of image delay time and maturity of scar. Magn Reson Med 2006; 55: 780-789.